Compare Stocks → Protect Yourself While There’s Still Time … (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:DFFNOTCMKTS:ICOTFOTCMKTS:NEVPFNASDAQ:NVUSNASDAQ:ONTX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDFFNDiffusion Pharmaceuticals$4.64$2.76▼$7.40$8.98M1.7810,937 shs351,000 shsICOTFiCo Therapeutics$0.33-2.9%$0.37$0.80▼$1.82$2.99M2.034,760 shs15,017 shsNEVPFAbliva AB (publ)$0.01$0.01$0.01▼$0.02N/AN/AN/AN/ANVUSNovus Therapeutics$2.06+2.0%$13.23$4.50▼$27.32$2.96M2.0778,851 shs81,544 shsONTXOnconova Therapeutics$0.84$0.55▼$1.45$20.90M1.3896,681 shs1.28 million shsThese 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDFFNDiffusion Pharmaceuticals0.00%0.00%0.00%0.00%-22.60%ICOTFiCo Therapeutics0.00%-12.66%-5.36%-13.49%-38.61%NEVPFAbliva AB (publ)0.00%0.00%0.00%-50.00%0.00%NVUSNovus Therapeutics0.00%+25.48%-7.08%+8.24%-12.05%ONTXOnconova Therapeutics0.00%0.00%+10.59%+40.84%-5.21%The “Next Bitcoin”? 10 CENT Crypto Set to Explode (Ad)The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…Click For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDFFNDiffusion PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AICOTFiCo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANEVPFAbliva AB (publ)N/AN/AN/AN/AN/AN/AN/AN/ANVUSNovus TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AONTXOnconova Therapeutics0.7669 of 5 stars3.53.00.00.00.00.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDFFNDiffusion PharmaceuticalsN/AN/AN/AN/AICOTFiCo TherapeuticsN/AN/AN/AN/ANEVPFAbliva AB (publ)N/AN/AN/AN/ANVUSNovus TherapeuticsN/AN/AN/AN/AONTXOnconova Therapeutics3.00Buy$11.00∞ UpsideCurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDFFNDiffusion PharmaceuticalsN/AN/AN/AN/A$6.97 per shareN/AICOTFiCo TherapeuticsN/AN/AN/AN/A($0.07) per shareN/ANEVPFAbliva AB (publ)N/AN/AN/AN/A$0.04 per shareN/ANVUSNovus TherapeuticsN/AN/AN/AN/A$13.13 per shareN/AONTXOnconova Therapeutics$230K0.00N/AN/A$1.35 per share0.00Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDFFNDiffusion Pharmaceuticals-$15.59MN/A0.00N/AN/AN/A-69.96%-62.98%N/AICOTFiCo Therapeutics-$1.11M-$0.40N/A∞N/AN/AN/A-288.85%N/ANEVPFAbliva AB (publ)-$8.45MN/A0.00∞N/AN/A-63.75%-57.93%N/ANVUSNovus Therapeutics-$16.01M-$21.58N/AN/AN/AN/A-133.49%-30.52%N/AONTXOnconova Therapeutics-$18.96M-$0.91N/AN/AN/A-8,930.97%-95.43%-61.19%5/20/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDFFNDiffusion PharmaceuticalsN/AN/AN/AN/AN/AICOTFiCo TherapeuticsN/AN/AN/AN/AN/ANEVPFAbliva AB (publ)N/AN/AN/AN/AN/ANVUSNovus TherapeuticsN/AN/AN/AN/AN/AONTXOnconova TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDFFNDiffusion PharmaceuticalsN/A10.7110.71ICOTFiCo TherapeuticsN/A0.720.72NEVPFAbliva AB (publ)N/A6.606.60NVUSNovus TherapeuticsN/A18.7818.78ONTXOnconova TherapeuticsN/A2.792.79OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDFFNDiffusion Pharmaceuticals9.95%ICOTFiCo TherapeuticsN/ANEVPFAbliva AB (publ)N/ANVUSNovus TherapeuticsN/AONTXOnconova Therapeutics7.95%Insider OwnershipCompanyInsider OwnershipDFFNDiffusion Pharmaceuticals1.80%ICOTFiCo TherapeuticsN/ANEVPFAbliva AB (publ)N/ANVUSNovus Therapeutics2.20%ONTXOnconova Therapeutics3.30%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableDFFNDiffusion Pharmaceuticals132.04 million2.00 millionNot OptionableICOTFiCo TherapeuticsN/A9.05 millionN/ANot OptionableNEVPFAbliva AB (publ)8N/AN/ANot OptionableNVUSNovus Therapeutics71.44 millionN/ANot OptionableONTXOnconova Therapeutics1621.00 million20.31 millionOptionableICOTF, NEVPF, DFFN, ONTX, and NVUS HeadlinesSourceHeadlineOnconova Therapeutics (NASDAQ:ONTX) Now Covered by StockNews.comamericanbankingnews.com - April 24 at 2:22 AMOnconova Therapeutics (NASDAQ:ONTX) Coverage Initiated at StockNews.comamericanbankingnews.com - April 16 at 2:22 AMOnconova and Trawsfynydd merge to form Traws Pharmauk.investing.com - April 4 at 6:50 PMTraws Pharma Full Year 2023 Earnings: Beats Expectationsfinance.yahoo.com - April 4 at 6:50 PMNewtown’s Onconova Therapeutics Secures $14 Million and New CEO in Merger with Trawsfynyddmsn.com - April 3 at 5:47 PMOnconova Acquires Trawsfynydd To Form Traws Pharmamarkets.businessinsider.com - April 2 at 10:00 AMTraws Pharma Announces New Employee Inducement Grantsglobenewswire.com - April 2 at 7:15 AMOnconova to Unveil New Rigosertib Study Results at Cancer Research Meetingmsn.com - March 12 at 8:48 AMAnalysts Offer Insights on Healthcare Companies: Onconova Therapeutics (ONTX) and Biogen (BIIB)markets.businessinsider.com - March 11 at 1:17 PMOnconova Therapeutics’ Rigosertib Poster Selected for AACR 2024finance.yahoo.com - March 8 at 9:56 AMOnconova Therapeutics' Rigosertib Poster Selected for AACR 2024globenewswire.com - March 8 at 8:00 AMOnconova Therapeutics Inc (ONTX)investing.com - February 13 at 12:22 AMOnconova Therapeutics, Inc. (ONTX)finance.yahoo.com - January 23 at 10:41 PMOnconova Therapeutics Stock (NASDAQ:ONTX) Dividends: History, Yield and Datesbenzinga.com - December 21 at 11:07 PMOnconova stock falls 10% on preclinical data for lymphoma drugmsn.com - December 12 at 4:02 PMOnconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphomafinance.yahoo.com - December 12 at 9:55 AMOnconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’sfinance.yahoo.com - December 8 at 6:47 PMOnconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conferencefinance.yahoo.com - November 28 at 10:06 AMOnconova Therapeutics, Inc. (NASDAQ:ONTX) Q3 2023 Earnings Call Transcriptfinance.yahoo.com - November 16 at 12:48 PMOnconova Therapeutics, Inc.: Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Resultsfinanznachrichten.de - November 16 at 1:30 AMOnconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Resultsfinance.yahoo.com - November 14 at 6:28 PMOnconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023finance.yahoo.com - November 7 at 5:22 PMOnconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCLbenzinga.com - November 2 at 7:56 PMOnconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCLfinance.yahoo.com - November 2 at 2:55 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsDiffusion PharmaceuticalsNASDAQ:DFFNDiffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. The company was founded in 2001 and is based in Charlottesville, Virginia.iCo TherapeuticsOTCMKTS:ICOTFSatellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.Abliva AB (publ)OTCMKTS:NEVPFAbliva AB (publ), a clinical-stage biotech company, develops medicines for the treatment of primary mitochondrial diseases. The company is developing KL1333 that is in Phase 2/3 clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT that is in Phase 1b/2a clinical study for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.Novus TherapeuticsNASDAQ:NVUSNovus Therapeutics, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). The company also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. Novus Therapeutics, Inc. is headquartered in Irvine, California.Onconova TherapeuticsNASDAQ:ONTXOnconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States. It has two clinical-stage programs, including narazaciclib, a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa study for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company also conducting a Phase II investigator-initiated study with rigosertib monotherapy in patients with advanced/metastatic squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa. It has a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib in China. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.